Actinium Pharmaceuticals, Inc.
ATNM- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001388320
No open-market purchases or sales by Actinium Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $5.18M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Actinium Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 74 | 1 | 72 | −1 |
| Shares | 7.25M | 1.88M | 8.46M | +3.09M (+57.5%) |
| Value | $53.6M | $13.9M | $15.9M | −$23.9M (−60.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,938,558 | $3.64M | 0.00% |
| Acadian Asset Management LLC | 453,694 | $851.0K | 0.00% |
| AQR Capital Management LLC | 359,353 | $675.6K | 0.00% |
| Qube Research & Technologies Ltd | 215,690 | $405.5K | 0.00% |
| Los Angeles Capital Management LLC | 171,180 | $321.8K | 0.00% |
| XTX Topco Ltd | 142,493 | $267.9K | 0.02% |
| Wellington Management Group LLP | 59,608 | $112.1K | 0.00% |
| Neuberger Berman Group LLC | 22,423 | $42.2K | 0.00% |
| Interchange Capital Partners, LLC | 19,646 | $36.9K | 0.01% |
| Man Group plc | 16,394 | $30.8K | 0.00% |
| Federated Hermes, Inc. | 2,000 | $3.76K | 0.00% |
| Steward Partners Investment Advisory, LLC | 2,000 | $3.76K | 0.00% |
| True Wealth Design, LLC | 472 | $888 | 0.00% |
| Capital Performance Advisors LLP | 437 | $822 | 0.00% |
| Cornerstone Planning Group LLC | 252 | $474 | 0.00% |
| Sterling Capital Management LLC | 31 | $58 | 0.00% |
| Capital Advisors, Ltd. LLC | 63 | $0 | 0.00% |
Sold out (18)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Schonfeld Strategic Advisors LLC | 141,830 | $1.05M |
| BIT Capital GmbH | 89,668 | $663.5K |
| ADAR1 Capital Management, LLC | 75,133 | $556.0K |
| Campbell & CO Investment Adviser LLC | 32,034 | $237.1K |
| Prosperity Wealth Management, Inc. | 31,000 | $229.4K |
| D. E. Shaw & Co., Inc. | 29,337 | $217.1K |
| Corton Capital Inc. | 20,281 | $150.1K |
| American Century Companies Inc | 18,023 | $133.4K |
| MetLife Investment Management | 15,276 | $113.0K |
| National Asset Management, Inc. | 13,006 | $96.2K |
| Manufacturers Life Insurance Company, The | 12,488 | $92.4K |
| Perritt Capital Management Inc | 12,000 | $88.8K |
| Voya Investment Management LLC | 10,633 | $78.7K |
| nVerses Capital, LLC | 2,200 | $16.3K |
| Leonteq Securities AG | 500 | $3.69K |
| Aviso Financial Inc. | 30 | $219 |
| Rothschild Investment LLC | 15 | $111 |
| Quest Partners LLC | 1 | $7 |
Not filed for Q3 2024 yet (1)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 1,875,425 | $13.9M |